drug · gene
exagamglogene autotemcel
Phase 3updated 6mo agoby $VERX Vertex, Inc.🔗 ChEMBL
Phase 3community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
indications
indications
Sickle Cell Disease
targets
B-cell lymphoma/leukemia 11A
all catalysts(0)
nothing on the calendar yet
News(10)
- nChroma halves workforce, BioXcel lets execs goFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2h ago
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict loomsAnalysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.biospace · 2d ago
- Genetix’s genetic medicines are officially profitable, with $327M in sales YTDIt’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech…biospace · 2d ago
- Marrow Therapeutics debuts with $173M to tackle blood disorders in vivoMarrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.biospace · 2d ago
- Marrow sets out to challenge genetic medicines for severe blood diseasesArmed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta tha…biopharma_dive · 2d ago
- Marrow extracts $120M series B to advance preclinical blood disease therapyA new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…fiercebiotech · 6d ago
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 9d ago
- Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdownGearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…fiercebiotech · 9d ago
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.biopharma_dive · 16d ago
- Plug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsFormer biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…biospace · 17d ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that